Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia

The requested reference [cac095831b3154b332147d68c7c0f4d8288cebf7] no longer exists in our database. It has been replaced by the current reference: [271a474c8280bf7264f2621db2b674c86c225fe3]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
EDP167 is a double‐stranded small interfering RNA (siRNA) drug targetingangiopoietin‐like 3 protein (ANGPTL3), which may bring benefits for patients withdyslipidemia conditions. This Phase 2 clinical study comprises two phases: a randomized,double‐blind, placebo parallel‐controlled core study and an open‐label extension study.
Epistemonikos ID: 0b9b34b2a21860bcef937d2a7018ce48349fca10
First added on: Sep 03, 2026